The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
GlobalData on MSN4d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
6d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Addresses the significant threat of antimicrobial resistance.
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback